BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36982155)

  • 1. LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects.
    Duprat F; Robles C; Castillo MP; Rivas Y; Mondaca M; Jara N; Roa F; Bertinat R; Toledo J; Paz C; González-Chavarría I
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
    Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
    World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic augments the uptake of oxidized LDL by upregulating the expression of lectin-like oxidized LDL receptor in mouse aortic endothelial cells.
    Hossain E; Ota A; Karnan S; Damdindorj L; Takahashi M; Konishi Y; Konishi H; Hosokawa Y
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):651-8. PubMed ID: 24145059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
    Morel KL; Hamid AA; Clohessy JG; Pandell N; Ellis L; Sweeney CJ
    Mol Cancer Res; 2021 Jul; 19(7):1137-1145. PubMed ID: 33863813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway.
    Ou HC; Chou WC; Hung CH; Chu PM; Hsieh PL; Chan SH; Tsai KL
    Environ Toxicol; 2019 Jul; 34(7):825-835. PubMed ID: 30963716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells.
    Lee WJ; Ou HC; Hsu WC; Chou MM; Tseng JJ; Hsu SL; Tsai KL; Sheu WH
    J Vasc Surg; 2010 Nov; 52(5):1290-300. PubMed ID: 20692795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native and Oxidized Low-Density Lipoproteins Increase the Expression of the LDL Receptor and the LOX-1 Receptor, Respectively, in Arterial Endothelial Cells.
    Catar R; Chen L; Zhao H; Wu D; Kamhieh-Milz J; Lücht C; Zickler D; Krug AW; Ziegler CG; Morawietz H; Witowski J
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
    Qiao J; Grabowska MM; Forestier-Roman IS; Mirosevich J; Case TC; Chung DH; Cates JM; Matusik RJ; Manning HC; Jin R
    Oncotarget; 2016 Sep; 7(38):61955-61969. PubMed ID: 27542219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L; Schweizer MT
    Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.